Complete resolution of hepatic aspergillosis after non-myeloablative hematopoietic stem cell transplantation in a patient with acute myeloid leukemia
Complete resolution of hepatic aspergillosis after non-myeloablative hematopoietic stem cell transplantation in a patient with acute myeloid leukemia
复制标题
DOI：
10.1080/10245330500141390
复制
发表时间：
2005-10-01
期刊：
影响因子：
1.9
通讯作者：
Lauria, F
中科院分区：
文献类型：
--
作者：
Marotta, G;Tozzi, M;Lauria, F
曲霉菌引起的真菌感染是移植相关死亡的常见原因。因此，伴有严重真菌感染的白血病患者通常被排除在常规同种异体移植之外。最近，一些作者提出了非骨髓消融性造血干细胞移植（HSCT）在这一亚组患者中的作用。我们使用这种治疗方法在第二次完全缓解（CR）的高危急性髓细胞白血病患者中，既存肝曲霉菌病对常规抗真菌治疗无效。同种异体干细胞移植3个月后观察到肝脏病变完全消退。我们的工作证实了以前的报告表明，非清髓性HSCT是有效的患者不适合传统的移植，因为侵袭性曲霉菌病。
Fungal infections due to Aspergillus are a frequent cause of transplant-related mortality. For this reason, leukemic patients with severe fungal infection are usually excluded from conventional allotransplantation. Recently, some authors suggested a role for non-myelo ablative hematopoietic stem cell transplantation (HSCT) in this subset of patients. We used this therapeutic approach in a patient with high-risk acute myeloid leukemia in second complete remission (CR) with pre-existing hepatic aspergillosis refractory to conventional anti-fungal therapy. A complete regression of hepatic lesions was observed after 3 months from allogeneic stem cell transplantation. Our work confirms previous reports suggesting that non-myeloablative HSCT is effective in patients not eligible for conventional transplantation because of invasive aspergillosis.